Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Adrenocortical Hyperfunction × Cabergoline × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pituitary Neoplasms 3 Pituitary ACTH Hypersecretion 2 Acromegaly 2 Prostatic Neoplasms 1 Neuroendocrine Tumors 1 Neoplasms 1 Melanoma 1 Dumping Syndrome 1 Brain Neoplasms 1 Adrenocortical Hyperfunction 1

Interventions

relacorilant 1 pembrolizumab 1 pasireotide 1 Cabergoline 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Novartis

Phase 2 Terminated

68 enrolled 25 charts

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon ⚡